Sarilumab plus standard of care <i>vs</i> standard of care for the treatment of severe COVID-19: a phase 3, randomized, open-labeled, multi-center study (ESCAPE study).

EClinicalMedicine · 2023 · PMC9999914 · PMID 36936403

Europe PMC DOI

hedged sentence

0.0630

closest p · 1.3× alpha

0.0630

boldest claim

The sentences

a trend toward significancep = 0.063so close (0.05 < p ≤ 0.1)

Nevertheless, the difference between the two arms only showed a trend toward significance ( p = 0.063).

also in 3,729 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.